The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma Biotechnology Inc (NASDAQ:PBYI) Nerlynx (neratinib).
- The first update added Nerlynx to the body of the guidelines for treating adjuvant HER2-positive Breast Cancer, with a recommendation for considering extended adjuvant neratinib for patients with HR-positive, HER2-positive disease with a perceived high risk of recurrence.
- The second update involved the inclusion of dose escalation to improve the tolerability of neratinib in the treatment of adjuvant HER2-positive Breast Cancer.
- Related: Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial.
- Up to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease), and in the ExteNET study, 57% of patients were found to have hormone-receptor-positive tumors.
- HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death.
- Price Action: PBYI shares are trading 9.16% higher at $2.86 during the premarket session on the last check Thursday.
